PULM - Pulmatrix, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.3680
+0.0030 (+0.82%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.3650
Open0.3800
Bid0.290 x 100
Ask0.439 x 500
Day's Range0.3613 - 0.3970
52 Week Range0.2810 - 2.1700
Volume456,445
Avg. Volume308,303
Market Cap18.152M
Beta (3Y Monthly)4.67
PE Ratio (TTM)N/A
EPS (TTM)-0.608
Earnings DateMay 3, 2018 - May 7, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • Pulmatrix Announces $3.0 Million Registered Direct Offering
    PR Newswire11 days ago

    Pulmatrix Announces $3.0 Million Registered Direct Offering

    LEXINGTON, Mass., Nov. 29, 2018 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (PULM) today announced that it has entered into a securities purchase agreement with an institutional investor, providing for the purchase and sale of 9,375,000 shares of common stock (or common stock equivalents) at a price of $0.32 per share in a registered direct offering, resulting in total gross proceeds of $3.0 million. The Company also agreed to issue unregistered warrants to the investor in a concurrent private placement to purchase up to 1 share of common stock for each share or common stock (or common stock equivalent) purchased with an exercise price of $0.39 per share.

  • Pulmatrix Announces Positive Final Results from the Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole
    PR Newswire19 days ago

    Pulmatrix Announces Positive Final Results from the Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole

    LEXINGTON, Mass., Nov. 21, 2018 /PRNewswire/ -- Pulmatrix, Inc. (PULM) announced the results of the completed first-in-human study of Pulmazole (PUR1900) — an inhaled iSPERSETM formulation of the anti-fungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.

  • Pulmatrix to Present Results from the Pulmazole (PUR1900) Phase 1/1b Study at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology
    PR Newswire25 days ago

    Pulmatrix to Present Results from the Pulmazole (PUR1900) Phase 1/1b Study at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology

    LEXINGTON, Mass., Nov. 15, 2018 /PRNewswire/ -- Pulmatrix, Inc. (PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases will present the results of the recently completed phase 1/1b clinical trial of Pulmazole, an inhaled dry-powder iSPERSE™ formulation of itraconazole, at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology in Seattle, Washington on November 17, 2018.

  • Pulmatrix Reports Q3 2018 Results
    PR Newswire25 days ago

    Pulmatrix Reports Q3 2018 Results

    LEXINGTON, Mass. , Nov. 14, 2018 /PRNewswire/ --  Pulmatrix, Inc. (NASDAQ: PULM) today reported its third quarter results. "We remain focused on advancing the clinical development of our Pulmazole ...

  • Who Owns Most Of Pulmatrix Inc (NASDAQ:PULM)?
    Simply Wall St.3 months ago

    Who Owns Most Of Pulmatrix Inc (NASDAQ:PULM)?

    A look at the shareholders of Pulmatrix Inc (NASDAQ:PULM) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual toRead More...

  • Pulmatrix to present pre-clinical data on PUR1800 (RV1162) at the European Respiratory Society International Congress
    PR Newswire3 months ago

    Pulmatrix to present pre-clinical data on PUR1800 (RV1162) at the European Respiratory Society International Congress

    LEXINGTON, Mass., Sept. 17, 2018 /PRNewswire/ -- Pulmatrix, Inc. (PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases will present preclinical data on the anti-inflammatory activity of PUR1800 (RV1162) at the ERS International Congress 2018 in Paris, France. Aidan Curran, PhD and Senior Director, Research at Pulmatrix Inc will present preclinical data in an abstract entitled "PUR1800 (RV1162), a novel narrow spectrum kinase Inhibitor, but not fluticasone, reduces TNFα-induced cytokine release by primary bronchial epithelial cells from healthy volunteers and COPD patients" at 8:30AM on Wednesday, September 19.

  • Pulmatrix to Present at the 20th Annual Rodman & Renshaw Global Investment Conference on September 5, 2018
    PR Newswire3 months ago

    Pulmatrix to Present at the 20th Annual Rodman & Renshaw Global Investment Conference on September 5, 2018

    As part of the presentation, Robert Clarke, Ph.D., chief executive officer of Pulmatrix, will provide an update on the Company's business and its pipeline of inhaled therapeutics. Among the highlights of the presentation will be positive data from a phase 1/1b clinical study of Pulmatrix's Pulmazole, an inhaled an inhaled iSPERSETM formulation of the anti-fungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma. Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology.

  • Pulmatrix Reports Q2 2018 Results
    PR Newswire4 months ago

    Pulmatrix Reports Q2 2018 Results

    LEXINGTON, Mass. , Aug. 3, 2018 /PRNewswire/ --  Pulmatrix, Inc. (NASDAQ: PULM) today reports its second quarter results. "We are pleased with the preliminary results of the three-part Phase 1/ 1b ...

  • Pulmatrix Announces the Formation of the Pulmazole Clinical Advisory Board to Support Future Development
    PR Newswire5 months ago

    Pulmatrix Announces the Formation of the Pulmazole Clinical Advisory Board to Support Future Development

    Members include experts in both clinical research and management of Allergic Bronchopulmonary Aspergillosis and Asthma LEXINGTON, Mass. , July 23, 2018 /PRNewswire/ --  Pulmatrix, Inc. (NASDAQ: PULM), ...

  • ACCESSWIRE5 months ago

    Free Technical Research on Riot Blockchain and Three More Biotech Equities

    LONDON, UK / ACCESSWIRE / July 20, 2018/ If you want a free Stock Review on RIOT sign up now at www.wallstequities.com/registration. On Thursday, July 19, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday’s market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Prothena Corp. PLC (NASDAQ: PRTA), PTC Therapeutics Inc. (NASDAQ: PTCT), Pulmatrix Inc. (NASDAQ: PULM), and Riot Blockchain Inc. (NASDAQ: RIOT).

  • Pulmatrix Announces Positive Top-Line Preliminary Results from Part 3 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole
    PR Newswire5 months ago

    Pulmatrix Announces Positive Top-Line Preliminary Results from Part 3 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole

    Single dose of Pulmazole safe and well tolerated in subjects with asthma PK analysis of sputum samples demonstrated ~50-fold higher lung exposure following inhalation of Pulmazole compared to oral Sporanox® ...

  • PR Newswire6 months ago

    Pulmatrix Announces Positive Top-Line Results from Parts 1 and 2 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole

    All doses were well tolerated in normal healthy volunteers in Parts 1 and 2 at up to 35 mg of itraconazole, the maximal dose planned Substantially lower systemic exposure (100- to 400-fold) was observed ...

  • Pulmatrix Announces Publication of Results from a Phase 1 Pharmacodynamic Study of PUR0200 in COPD Patients
    PR Newswire6 months ago

    Pulmatrix Announces Publication of Results from a Phase 1 Pharmacodynamic Study of PUR0200 in COPD Patients

    LEXINGTON, Mass., June 13, 2018 /PRNewswire/ -- Pulmatrix, Inc. (PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today the publication of data from a dose-ranging Phase 1 clinical study of PUR0200 in COPD patients. PUR0200 is a once-daily, reformulation of tiotropium bromide for COPD patients and is being developed as a branded alternative to Spiriva® HandiHaler®. In the published study, moderate-to-severe COPD patients were administered one of three PUR0200 doses (3mg, 6mg or 9mg tiotropium bromide), Spiriva HandiHaler (18mg tiotropium bromide) or placebo in a 5 period cross-over study design.

  • Pulmatrix Announces Approval of Proposals Submitted to Company's Stockholders
    PR Newswire6 months ago

    Pulmatrix Announces Approval of Proposals Submitted to Company's Stockholders

    Election of three directors (Steven Gillis, Ph.D., Terrance G. McGuire and Amit D. Munshi) to serve as Class I directors on the company's Board of Directors to serve until the 2021 Annual Meeting of Stockholders or until successors have been duly elected and qualified. Amendment of the Company's Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan to (i) increase the total number of shares of common stock authorized for issuance under such plan to 12,500,000 shares and (ii) modify such plan's "evergreen" provision so that on January 1st of each year the number of shares reserved for issuance under such plan will automatically increase by 5% of the number of outstanding shares of common stock on such date. Amendment of the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 to 200,000,000 shares.

  • ACCESSWIRE6 months ago

    Wired News - Madrigal Pharma Reported Encouraging Top-line Data at 36 Weeks from Phase-2 Clinical Trial of MGL-3196 in Patients with NASH

    LONDON, UK / ACCESSWIRE / June 4, 2018 / If you want access to our free research report on Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=MDGL as the Company's latest news hit the wire. On May 31, 2018, the Company announced positive top-line, 36-week results from a Phase-2 clinical trial assessing MGL-3196, a first-in-class, oral, once-daily, liver-directed, thyroid hormone receptor (THR) β-selective agonist, in patients with biopsy-proven non-alcoholic steatohepatitis (NASH). Active-Investors.com is currently working on the research report for Pulmatrix, Inc. (NASDAQ: PULM), which also belongs to the Healthcare sector as the Company Madrigal Pharma.

  • ACCESSWIRE6 months ago

    Initiating Free Research Reports on Pulmatrix and Three Other Biotech Equities

    Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Proteostasis Therapeutics Inc. (NASDAQ: PTI), Prothena Corp. PLC (NASDAQ: PRTA), PTC Therapeutics Inc. (NASDAQ: PTCT), and Pulmatrix Inc. (NASDAQ: PULM).

  • Interested In Pulmatrix Inc (NASDAQ:PULM)? Here’s How It Performed Recently
    Simply Wall St.7 months ago

    Interested In Pulmatrix Inc (NASDAQ:PULM)? Here’s How It Performed Recently

    In this commentary, I will examine Pulmatrix Inc’s (NASDAQ:PULM) latest earnings update (31 March 2018) and compare these figures against its performance over the past couple of years, as wellRead More...

  • Pulmatrix selected to present company profile at the 2018 Respiratory Innovation Summit in San Diego
    PR Newswire7 months ago

    Pulmatrix selected to present company profile at the 2018 Respiratory Innovation Summit in San Diego

    LEXINGTON, Mass., May 17, 2018 /PRNewswire/ -- Pulmatrix, Inc. (PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases has been selected to present at the 2018 Respiratory Innovation Summit at the Manchester Grand Hyatt in San Diego.  Pulmatrix CEO Robert Clarke, PhD, will present the company profile in the Drug Delivery & Diagnostics Company Showcase at 10:50AM PDT on May 19, 2018.

  • Pulmatrix Reports Q1 2018 Results
    PR Newswire7 months ago

    Pulmatrix Reports Q1 2018 Results

    LEXINGTON, Mass. , May 11, 2018 /PRNewswire/ --  Pulmatrix, Inc. (NASDAQ: PULM) today reports its first quarter results. "We reached a major milestone for our Pulmazole program in the first quarter ...

  • Pulmatrix Announces Pricing Of $15.2 Million Underwritten Public Offering
    PR Newswire8 months ago

    Pulmatrix Announces Pricing Of $15.2 Million Underwritten Public Offering

    LEXINGTON, Mass., March 29, 2018 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (PULM) today announced the pricing of an underwritten public offering of an aggregate of 23,500,000 units. Each unit is comprised of one share of common stock (or common stock equivalent), one Series A warrant to purchase one share of common stock and one Series B warrant to purchase one share of common stock.

  • Pulmatrix Reports 2017 Financial Results; Provides 2018 Outlook on Pulmonary Disease Pipeline
    PR Newswire9 months ago

    Pulmatrix Reports 2017 Financial Results; Provides 2018 Outlook on Pulmonary Disease Pipeline

    LEXINGTON, Mass. , March 13, 2018 /PRNewswire/ --  Pulmatrix, Inc . (NASDAQ: PULM) today announces 2017 financial results, reviews the Company's recent progress, and provides an outlook for its pulmonary ...

  • Is Pulmatrix Inc (NASDAQ:PULM) A Financially Sound Company?
    Simply Wall St.9 months ago

    Is Pulmatrix Inc (NASDAQ:PULM) A Financially Sound Company?

    Investors are always looking for growth in small-cap stocks like Pulmatrix Inc (NASDAQ:PULM), with a market cap of US$31.15M. However, an important fact which most ignore is: how financially healthyRead More...

  • Pulmatrix Announces First Subject Dosed in Phase 1 Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole
    PR Newswire10 months ago

    Pulmatrix Announces First Subject Dosed in Phase 1 Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole

    ABPA is a disease that occurs most often in patients with underlying asthma or cystic fibrosis, and it is characterized by an exaggerated allergic hypersensitivity response of the immune system to the fungus Aspergillus growing in the airways. Oral itraconazole (Sporanox®) is currently used as an adjunctive treatment to corticosteroids in ABPA patients.

  • ACCESSWIRE10 months ago

    Today’s Research Reports on Trending Tickers: Atossa Genetics and Pulmatrix

    NEW YORK, NY / ACCESSWIRE / January 29, 2018 / All three major indexes closed the week at record highs Friday as corporate earnings continue to impress investors. The Dow Jones Industrial Average gained ...

  • Is Pulmatrix Inc (NASDAQ:PULM) Undervalued?
    Simply Wall St.10 months ago

    Is Pulmatrix Inc (NASDAQ:PULM) Undervalued?

    Pulmatrix Inc (NASDAQ:PULM), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqGM over the last few months. As aRead More...